Cytokine profile in relapsing-remitting Multiple sclerosis patients and the association between progression and activity of the disease

Molecular Medicine Reports

Volumn 7, Issue 3, 2013, Pages 1010-1020

  Kallaur, Ana Paula ^a   Oliveira, Sayonara Rangel ^a   Simao, Andréa Name Colado ^b   De Almeida, Elaine Regina Delicato ^b   Morimoto, Helena Kaminami ^b   Lopes, Josiane ^a   De Carvalho Jennings Pereira, Wildea Lice ^b   Andrade, Renato Marques ^b   Pelegrino, Larissa Muliterno ^b   Borelli, Sueli Donizete ^c   Kaimen Maciel, Damácio Ramon ^b   Reiche, Edna Maria Vissoci ^b  

^a Health Sciences Postgraduate Program   (Brazil)

^b STATE UNIVERSITY OF LONDRINA   (Brazil)

^c STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Cytokines; Disability; Disease activity; Disease progression; Multiple sclerosis

Indexed keywords

CYTOKINE; GADOLINIUM; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISABILITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; YOUNG ADULT;

EID: 84873111782     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1256     Document Type: Article

References (76)

1. Sospedra M and Martin M: Immunology of multiple sclerosis. Annals Review Immunology 23:683-747, 2005. (Pubitemid 40563183)
2. Cucci A, Barbero P, Clerico M, Ferrero B, Versino E, Contessa G, Demercanti S, Viglietta E, Di Liberto A, Vai AG and Durelli L: Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon. beta dose. J Neuroimmunol 226:150-157, 2010.
3. Graber JJ, Ford D, Zhan M, Francis G, Panitch H and Dhib-Jalbut S: Cytokine changes during interferon. beta therapy in multiple sclerosis: correlation with interferon dose and MRI response. J Neuroimmunol 185:168-174, 2007. (Pubitemid 46497443)
4. Dihb-Jalbut S, Arnold DL, Cleveland DW, Fisher M, Friedlander RM, Mouradian MM, Przedborski S, Trapp BD, Wyss-Coray T and Yong VW: Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol 176:198-215, 2006. (Pubitemid 44080333)
5. Huang WX, Huang P and Hillert J: Increased expression of caspase.1 and interleukin. 18 in peripheral blood mononuclear cells in patients with multiple sclerosis. Mult Scler 10:482-487, 2004. (Pubitemid 39207218)
6. Imitola J, Chitnis T and Khoury SJ: Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther 106:163-177, 2005. (Pubitemid 40603863)
7. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC and Mills KH: Interleukin. 1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 31:331-341, 2009.
8. Sweeney CM, Lonergan R, Basdeo SA, Kinsella K, Dungan LS, Higgins SC, Kelly PJ, Costelloe L, Tubridy N, Mills KH and Fletcher JM: IL-27 mediates the response to IFN.β therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav Immun 25:1170-1181, 2011.
9. Domingues HS, Mues M, Lassmann H, Wekerle H and Krishnamoorthy G: Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. PLoS One 5:e15531, 2010.
10. Rudick RA and Rosahoff RM: Cytokine secretion by multiple sclerosis monocytes. Arch Neurol 49:265-270, 1992.
11. Duddy ME, Armstrong MA, Crockard AD and Hawkins SA: Changes in plasma cytokines induced by interferon. beta 1a treatment in patients with multiple sclerosis. J Neuroimmunol 101:98-109, 1999. (Pubitemid 29505178)
12. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452, 1983. (Pubitemid 14237132)
13. Kermode AG, Thompson AJ, Tofts P, Macmanus DG, Kendall BE, Kingsley DP, Moseley IF, Rudge P and McDonald WI: Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 113:1477-1489, 1990. (Pubitemid 20385925)
14. Barkhof F: MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler 5:283-286, 1999. (Pubitemid 29405626)
15. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Luer W and Poser S: Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 44:1523-1526, 1994. (Pubitemid 24247453)
16. Olsson T: Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology 45(Suppl 6):S11-S15, 1995.
17. Okuda Y, Sakoda S, Fujimura H, Saeki Y, Kishimoto T and Yanagihara T: IL-6 plays a crucial role in the induction phase of myelin olygodendrocyte glucoprotein 35.55 induced experimental autoimmune encephalocyelitis. J Neuroimmunol 10:188-196, 1999. (Pubitemid 29516459)
18. Kraus J, Kuehne BS, Tofighi J, Frielinghaus P, Stolz E, Blaes F, Laske C, Engelhardt B, Traupe H, Kaps M and Oschmann P: Serum cytokine levels do not correlate with disease activity and severity assessed by brain MRI in multiple sclerosis. Acta Neurol Scand 105:300-308, 2002. (Pubitemid 34407234)
19. Trenova AG, Manova MG, Kostadinova II, Hrsitova DR, Vasileva TV and Zahariev ZI: Clinical and laboratory study of pro-inflammatory and anti-inflammatory cytokines in women with multiple sclerosis. Folia Med (Plovdiv) 53:29-35, 2011.
20. Obradović D, Kataranovski M, Dincić E, Obradović S and Colić M: Tumor necrosis factor-alpha and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis. Vojnosanit Pregl 69:151-156, 2012.
21. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, Mcfarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG and Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 58:840-846, 2005. (Pubitemid 41746873)
22. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor PK, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinchenker BG and Wolinsky JS: Diagnostic Criteria for Multiple Sclerosis: 2010 Revision to the McDonald Criteria. Am Neurol 69:292-302, 2011.
23. Lublin FD and Reingold SC: Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907-911, 1996.
24. Kamali-Sarvestani E, Nikseresht A, Aflaki E, Sarvari J and Gharesi-Fard B: TNF-α, TNF-β and IL-4 gene polymorphisms in Iranian patients with multiple sclerosis. Acta Neurol Scand 115:161-166, 2007. (Pubitemid 46219208)
25. Wu J-S, James I, Qiu W, Castley A, Christiansen FT, Carroll WM, Mastaglia FL and Kermode AG: HLA-DRB1 allele heterogeneity influences multiple sclerosis severity as well as risk in Western Australia. J Neuroimmunol 219:109-113, 2010.
26. Comini-Frota ER, Rodrigues DH, Miranda EC, Drum DG, Kaimen-Maciel DR, Donadi EA and Teixeira AL: Serum levels of brain. derived neurotrophic factor correlate with the number of T2 MRI lesions in multiple sclerosis. Braz J Med Biol Res 45:68-71, 2012.
27. Ministry of Health National Health Surveillance Agency Board (ANVISA): Resolution RDC no. 153, June 14, 2004. Official Gazette: 24 Jun, 2004, Brazil (In Portuguese).
28. Teunissem CE, Petzold A, Bennetm JL, Berven FS, Brudin L, Comabella M, Franciotta D, Frederiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johson MH, Krasulova E, Kuhle J, Magnone MC, Rjda C, Schimidt HK, Van Pesch V, Waubant E, Wolf C, Giovannoni G, Hemmer B, Tumani H and Deisenhammer F: A consensus protocol of the standardization of cerebral fluid collection and biobanking. Neurology 73:1914-1922, 2009.
29. Bielekova B and Martin R: Development of biomarkers in multiple sclerosis. Brain 127:1463-1478, 2004. (Pubitemid 38899400)
30. Giovannoni G, Green AJ and Thompson EJ: Are there any body fluid markers of brain atrophy in multiple sclerosis? Mult Scler 4:138-142, 1998. (Pubitemid 28410040)
31. Luomala M, Lehtimaki T, Huhtala H, Ukkonen M, Koivula T, Hurme H and Elovaara I: Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol Scand 108:396-400, 2003. (Pubitemid 37464118)
32. Pulkkinen K, Luomala M, Kuusisto H, Lehtimaki T, Saarela M, Jalonen TO and Elovaara I: Increased in CCR5 Delta32/Delta32 genotype in multiple sclerosis. Acta Neurol Scand 109:342-347, 2004. (Pubitemid 38580902)
33. Bahreini SA, Jabalameli MR, Saadatnia M and Zahednasab H: The role of non. HLA single nucleotide polymorphisms in multiple sclerosis susceptibility. J Neuroimmunol 229:5-15, 2010.
34. Voskuhl RR and Gold SM: Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol 8:255-263, 2012.
35. Ebers GC: PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double blind placebo controlled study interferon beta 1a in relapsing/remitting multiples sclerosis. Lancet 352:1498-1504, 1998.
36. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH and van den Noort S: Disease modifying therapies in multiple sclerosis: reports of the therapeutics and technology assessment subcommittee of American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 22:169-178, 2002. (Pubitemid 34086933)
37. Raivich G and Banati R: Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. Brain Res Rev 46:161-181, 2004.
38. Chen YC, Yang X, Miao L, Liu ZG, Li W, Zhao ZX, Sun XL, Jiang GX, Chen SD and Cheng Q: Serum level of interleukin. 6 in Chinese patients with multiple sclerosis. J Neuroimmunol 15:109-111, 2012.
39. Nguyen LT, Ramanathan M, Weinstock-Guttman B, Baier M, Brownscheidle C and Jacobs LD: Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. J Neurol Sci 209:93-99, 2003. (Pubitemid 36401607)
40. Ramgolam VS, Sha Y, Jin J, Zhang X and Markovic-Plese S: IFN-beta inhibits human Th17 cell differentiation. J Immunol 183:5418-5427, 2009.
41. John GR, Lee SC, Song X, Rivieccio M and Brosnan CF: IL-1-regulated responses in astrocytes: relevance to injury and recovery. Glia 49:161-176, 2005. (Pubitemid 40188496)
42. Carlson NG, Wieggel WA, Chen J, Bacchi A, Rogers SW and Gahring LC: Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6 and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. J Immunol 163:3963-3968, 1999. (Pubitemid 29450925)
43. Navikas V, Matusevicius D, Soderstrom M, Fredrikson S, Kivisakk P, Ljungdahl A, Hojeberg B and Link H: Increased interleukin. 6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis. J Neuroimmunol 64:63-69, 1996. (Pubitemid 26052075)
44. Imamura K, Suzumura A, Hayashi F and Marunouchi T: Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. Acta Neurol Scand 87:281-285, 1993. (Pubitemid 23122221)
45. Eugster HP, Frei K, Kopf M, Lassmann H and Fontana A: IL-6-deficient-mice resist myelin oligodendrocyte glycoprotein. induced autoimmune encephalomyelitis. Eur J Immunol 28:2178-2187, 1998. (Pubitemid 28321302)
46. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC and Dinarello CA: Correlations and interactions in the production of interleukin-6 (IL-6), IL-1 and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 75:40-47, 1990. (Pubitemid 20031487)
47. Tilg H, Trehu E, Atkins MB, Dinarello CA and Mier JW: Interleukin. 6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83:113-118, 1994. (Pubitemid 24016522)
48. Navikas V, Link J, Palasik W, Soderstrom M, Fredrikson S, Olsson T and Link H: Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. Scand J Immunol 41:171-178, 1995.
49. Hirano T: Interleukin-6. In: The Handbook of Cytokines. Thompson (ed.) Academic Press, London, pp145-169, 1994.
50. Cooke A: Th17 cells in inflammatory conditions. Rev Diabet Stud 3:72-75, 2006.
51. Brucklacher-Waldert V, Stuerner K, Kolster M, Wolthausen J and Tolosa E: Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 132:3329-3341, 2009.
52. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, Mcclanahan T, Kastelein RA and Cua DJ: IL.23 drives a pathogenesis T cell population that induces autoimmune inflammation. J Exp Med 20:233-240, 2005. (Pubitemid 40189432)
53. Harrington LE, Mangan PR and Weaver CT: Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opn Immunol 18:349-356, 2006.
54. Van Wagoner NJ and Benveniste EN: Interleukin. 6 expression and regulation in astrocytes. J Neuroimmunol 100:124-139, 1999.
55. Windhagen A, Newcombe J, Dangond F, Strand C, Woodroof MN, Cuzner ML and Hafler DA: Expression of costimulatory molecules B7.1(CD28), B7.2 (CD86) and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 182:1985-1996, 1995.
56. Campbell IL, Stalder AK, Akwa Y, Pagenstecher A and Asensio VC: Transgenic models to study the actions of cytokines in the central nervous system. Neuroimmunomodulation 5:126-135, 1998. (Pubitemid 28417024)
57. Byrnes AA, Mcarthur JC and Karp CL: Interferon. beta therapy for multiple sclerosis induces reciprocal changes in interleukin. 12 and interleukin. 10 production. Ann Neurol 51:165-174, 2002. (Pubitemid 34111438)
58. Wang X, Chen M, Wandinger KP, Willians G and Dhib-Jalbut S: IFN-beta.1b inhibits IL.12 production in peripheral blood mononuclear cells in an IL.10.dependent mechanism: relevance to IFN-beta.1b therapeutic effects in multiple sclerosis. J Immunol 165:548-557, 2000. (Pubitemid 30429550)
59. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N and Glimcher LH: B7.1 and B7.2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707-718, 1995.
60. Mikulkova Z, Praksova P, Stourac P, Bednarik J and Michalek J: Imbalance in T-cell and cytokine profiles in patients with relapsing-remitting multiple sclerosis. J Neurol Sci 300:135-141, 2011.
61. Begolka WS and Miller SD: Cytokines as intrinsic and exogenous regulators of pathogenesis in experimental autoimmune encephalomyelitis. Res Immunol 149:771-781, 1998.
62. Cannella B and Raine CS: The adhesion molecule and cytokine profile of multiple sclerosis lesions. Annals Neurol 37:424-435, 1995.
63. Samoilova EB, Horton JL and Chen Y: Acceleration of experimental autoimmune encephalomyelitis in interleukin. 10.deficient mice: roles of interleukin. 10 in disease progression and recovery. Cell Immunol 188:118-124, 1998. (Pubitemid 28493564)
64. Marques M: Multiple sclerosis - Forms and phases of the disease. In: Multiple Sclerosis Introduction. Pedrosa R (ed). Elaborated by the Neurology Portuguese Society. 1st edition. Biogen Indec Portugal, Lisboa, pp155-161, 2010.
65. Brandao CO, Ruocco HH, Farias Ados S, Oliveira C, Hallal-Longo DE, Mirandola SR, Oliveira EC, Cendes F, Damasceno BP and Santos LM: Cytokines and intrathecal IgG synthesis in multiple sclerosis patients during clinical remission. Arq Neuro Psiquiatr 63:914-919, 2005. (Pubitemid 43211521)
66. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H and Wietzerbin J: Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestations in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 78:318-323, 1998.
67. Becher B, Giacomini PS, Pelletier D, Mccrea E, Prat A and Antel JP: Interferon. gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon. beta therapy. Ann Neurol 45:247-250, 1999. (Pubitemid 29072372)
68. Pouly S, Becher B, Blain M and Antel JP: Interferon. gamma modulates human oligodendrocyte susceptibility to Fas-mediated apoptosis. J Neuropathol Exp Neurol 59:280-286, 2000. (Pubitemid 30183695)
69. Ehling R, Gassner Ch, Lutterotti A, Strasser-Fuchs S, Kollegger H, Kristoferitsh W, Reindl M and Berger T: Genetic variants in the tumor necrosis factor receptor II gene in patients with multiple sclerosis. Tissue Antigens 63:28-33, 2004. (Pubitemid 38130439)
70. Benvenuto R, Paroli M, Buttinelli C, Franco A, Barnaba V, Fieschi C and Balsano F: Tumor necrosis factor-alpha synthesis by cerebrospinal-fluid-derived T cell clones from patients with multiple sclerosis. Clin Exp Immunol 84:97-102, 1991.
71. Selmaj K, Raine CS, Cannella B and Brosnan CF: Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 87:949-954, 1991.
72. Schonrock LM, Gawlowski G and Bruck W: Interleukin. 6 expression in human multiple sclerosis lesions. Neurosci Lett 294:45-48, 2000.
73. van Boxel-Dezaire AH, Hoff SC, Van Oosten BW, Verweij CL, Drager AM, Ader HJ, Van Houwelingen JC, Barkhof F, Polman CH and Nagelkerkern L: Decreased interleukin. 10 and increased interleukin. 12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 45:695-703, 1999. (Pubitemid 29260746)
74. Iwakura Y and Ishigame H: The IL-23/IL-17 axis in inflammation. J Clin Invest 116:1218-1222, 2006.
75. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R and Steinman L: Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8:500-508, 2002. (Pubitemid 34546753)
76. Pelfrey CM, Rudick RA, Cotleur AC, Lee JC, Tary-Lehmann M and Lehmann PV: Quantification of self-recognition in multiple sclerosis by single cell analysis of cytokine production. J Immunol 165:1641-1651, 2000. (Pubitemid 30604603)